BCM
BMRN icon

Bluefin Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bluefin Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,500
Closed -$32K – 400
2020
Q1 		$32K Sell
12,500
-137,800
-92% -$11.9M ﹤0.01% 338
2019
Q4 		$88K Buy
+150,300
New +$11.4M 0.01% 422

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Bluefin Capital Management's BMRN Position: Q3 2019 in Review

Bluefin Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 8,400 shares — an estimated $719K sold.

Bluefin Capital Management first reported a position in BMRN in Q2 2015 and held it in 2 quarters. The position peaked at $1.67M in Q2 2015. 436 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

  • Bluefin Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Bluefin Capital Management sold 8,400 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $719K.
  • Bluefin Capital Management first reported a position in BioMarin Pharmaceuticals in Q2 2015 and held it in 2 quarters.
  • Bluefin Capital Management's BioMarin Pharmaceuticals position peaked at $1.67M in Q2 2015.
  • 436 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Bluefin Capital Management's 13F filing for Q3 2019, filed 15 Nov 2019.